AQST
Aquestive Therapeutics Inc
NASDAQ · Pharmaceuticals
$4.11
+0.27 (+7.03%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 80.97M | 77.69M | 128.24M | 128.94M | 106.66M |
| Net Income | -62,087,381 | -53,610,901 | 31.04M | 33.13M | 27.21M |
| EPS | — | — | — | — | — |
| Profit Margin | -76.7% | -72.9% | 24.2% | 25.7% | 25.5% |
| Rev Growth | +4.2% | +4.2% | +19.4% | +19.1% | -7.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 206.60M | 206.60M | 158.79M | 204.59M | 185.15M |
| Total Equity | 44.12M | 44.12M | 375.07M | 356.51M | 373.84M |
| D/E Ratio | 4.68 | 4.68 | 0.42 | 0.57 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -50,289,680 | -45,836,319 | 59.39M | 53.66M | 42.58M |
| Free Cash Flow | — | — | 29.99M | 23.71M | 15.65M |